165 related articles for article (PubMed ID: 12614214)
21. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
Valentino LA; Cooper DL; Goldstein B
Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
[TBL] [Abstract][Full Text] [Related]
22. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
[TBL] [Abstract][Full Text] [Related]
23. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
24. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of using recombinant factor VIIa in continuous infusion.
Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
[TBL] [Abstract][Full Text] [Related]
26. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.
Santagostino E; Escobar M; Ozelo M; Solimeno L; Arkhammar P; Lee HY; Rosu G; Giangrande P
Blood Rev; 2015 Jun; 29 Suppl 1():S9-18. PubMed ID: 26073369
[TBL] [Abstract][Full Text] [Related]
27. Massive pseudotumour resection with recombinant factor VIIa (NovoSeven) cover.
O'Connell N; Chen J; Byrne M; O'Shea E; Smyth H; Smith OP
Br J Haematol; 2002 Mar; 116(3):645-8. PubMed ID: 11849225
[TBL] [Abstract][Full Text] [Related]
28. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.
Polyanskaya T; Zorenko V; Karpov E; Sampiev M; Mishin G; Vasiliev D
Haemophilia; 2012 Nov; 18(6):997-1002. PubMed ID: 22672066
[TBL] [Abstract][Full Text] [Related]
29. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
Smith OP
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
[TBL] [Abstract][Full Text] [Related]
30. Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
Hedner U
Dis Mon; 2003 Jan; 49(1):39-48. PubMed ID: 12525827
[TBL] [Abstract][Full Text] [Related]
31. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery.
Coppola A; Windyga J; Tufano A; Yeung C; Di Minno MN
Cochrane Database Syst Rev; 2015 Feb; (2):CD009961. PubMed ID: 25922858
[TBL] [Abstract][Full Text] [Related]
32. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
[TBL] [Abstract][Full Text] [Related]
33. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
Pruthi RK; Mathew P; Valentino LA; Sumner MJ; Seremetis S; Hoots WK;
Thromb Haemost; 2007 Oct; 98(4):726-32. PubMed ID: 17938794
[TBL] [Abstract][Full Text] [Related]
34. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
Giangrande PL; Wilde JT; Madan B; Ludlam CA; Tuddenham EG; Goddard NJ; Dolan G; Ingerslev J
Haemophilia; 2009 Mar; 15(2):501-8. PubMed ID: 19187194
[TBL] [Abstract][Full Text] [Related]
35. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody.
Gringeri A; Santagostino E; Mannucci PM
Haemostasis; 1991; 21(1):1-4. PubMed ID: 1907588
[TBL] [Abstract][Full Text] [Related]
36. Recombinant activated factor VII in patients at high risk of bleeding.
Kubisz P; Stasko J
Hematology; 2004; 9(5-6):317-32. PubMed ID: 15763970
[TBL] [Abstract][Full Text] [Related]
37. Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma.
Scharling B; Nielsen GG; Klitgaard T; Skovsted TA; Møss J; Segel S; Larsen LF
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):677-84. PubMed ID: 17890956
[TBL] [Abstract][Full Text] [Related]
38. Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors.
Kenet G; Lubetsky A; Luboshitz J; Ravid B; Tamarin I; Varon D; Martinowitz U
Haemophilia; 2009 Sep; 15(5):1065-73. PubMed ID: 19486172
[TBL] [Abstract][Full Text] [Related]
39. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
[TBL] [Abstract][Full Text] [Related]
40. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
